Mrna
Found 3 recent publications
Moderna recorded the sharpest stock increase in the S&P 500 index since 2008
Breaking an 18-year record: The success of clinical trials combining mRNA technology in the fight against cancer has led to an unprecedented surge in Moderna's stock. According to The Wall Street Journal, the company recorded the sharpest daily increase of any S&P 500 firm since 2008.
Senior Health Ministry official on the new flu vaccine: "It is identical to the coronavirus vaccines" | Listen
Prof. Tal Brosh, Director of the Infectious Diseases Unit at Assuta Ashdod Hospital, explained on 103fm radio about the mRNA flu vaccine approved in the US: "In the coming season, it will certainly not be relevant."
After decades: A new flu vaccine has been approved that may change the rules of the game
The US Food and Drug Administration (FDA) has approved Moderna's Mfalusiva, the first seasonal flu vaccine based on mRNA technology. In a large-scale trial, the vaccine showed a 26.6% higher relative efficacy compared to a standard-dose flu vaccine.